IOL Chemicals and Pharmaceuticals Limited (IOLCP.BO)
INR 60.95
(1.96%)
INR 60.95
(1.96%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 1.09 Billion INR | -31.6% |
| 2022 | 4.44 Billion INR | 25.12% |
| 2021 | 3.55 Billion INR | 32.25% |
| 2020 | 2.68 Billion INR | 11.72% |
| 2019 | 2.4 Billion INR | 14.16% |
| 2018 | 2.1 Billion INR | 31.2% |
| 2017 | 1.6 Billion INR | 14.53% |
| 2016 | 1.4 Billion INR | 1.6% |
| 2015 | 1.38 Billion INR | 12.14% |
| 2014 | 1.23 Billion INR | -4.89% |
| 2013 | 1.29 Billion INR | 4.52% |
| 2012 | 1.23 Billion INR | -1.66% |
| 2011 | 1.25 Billion INR | -9.24% |
| 2010 | 1.38 Billion INR | 262.88% |
| 2009 | 382.36 Million INR | 36.14% |
| 2008 | 280.86 Million INR | -8.98% |
| 2007 | 308.56 Million INR | 97.2% |
| 2006 | 156.46 Million INR | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 618.5 Million INR | -24.78% |
| 2023 FY | 3.04 Billion INR | -31.6% |
| 2023 Q4 | 822.3 Million INR | -39.73% |
| 2023 Q3 | 1.36 Billion INR | -4.77% |
| 2023 Q2 | 1.43 Billion INR | 2.23% |
| 2023 Q1 | 1.4 Billion INR | 73.75% |
| 2022 Q4 | 806.6 Million INR | -33.02% |
| 2022 Q2 | 1.18 Billion INR | -6.03% |
| 2022 Q1 | 1.25 Billion INR | 88.41% |
| 2022 FY | 4.44 Billion INR | 25.12% |
| 2022 Q3 | 1.2 Billion INR | 2.0% |
| 2021 Q1 | 836.1 Million INR | 113.84% |
| 2021 Q3 | 1.06 Billion INR | 6.92% |
| 2021 FY | 3.55 Billion INR | 32.25% |
| 2021 Q2 | 991.8 Million INR | 18.62% |
| 2021 Q4 | 666.9 Million INR | -37.11% |
| 2020 Q1 | 691.1 Million INR | 231.78% |
| 2020 Q4 | 391 Million INR | -50.74% |
| 2020 Q2 | 812.5 Million INR | 17.57% |
| 2020 FY | 2.68 Billion INR | 11.72% |
| 2020 Q3 | 793.7 Million INR | -2.31% |
| 2019 Q3 | 714 Million INR | -1.49% |
| 2019 Q1 | 759.2 Million INR | 405.12% |
| 2019 FY | 2.4 Billion INR | 14.16% |
| 2019 Q4 | 208.3 Million INR | -70.83% |
| 2019 Q2 | 724.8 Million INR | -4.53% |
| 2018 Q3 | 735.5 Million INR | 9.61% |
| 2018 Q2 | 671 Million INR | 17.45% |
| 2018 Q1 | 571.3 Million INR | 13.65% |
| 2018 FY | 2.1 Billion INR | 31.2% |
| 2018 Q4 | 150.3 Million INR | -79.56% |
| 2017 Q3 | 531.7 Million INR | 12.05% |
| 2017 FY | 1.6 Billion INR | 14.53% |
| 2017 Q4 | 502.7 Million INR | -5.45% |
| 2017 Q1 | 455.6 Million INR | 12.74% |
| 2017 Q2 | 474.5 Million INR | 4.15% |
| 2016 FY | 1.4 Billion INR | 1.6% |
| 2016 Q4 | 404.1 Million INR | -1.46% |
| 2016 Q3 | 410.1 Million INR | 2.86% |
| 2016 Q2 | 398.7 Million INR | 7.82% |
| 2016 Q1 | 369.8 Million INR | 5.1% |
| 2015 Q2 | 367 Million INR | -1.34% |
| 2015 Q4 | 351.86 Million INR | -2.21% |
| 2015 FY | 1.38 Billion INR | 12.14% |
| 2015 Q1 | 371.98 Million INR | 16.08% |
| 2015 Q3 | 359.8 Million INR | -1.96% |
| 2014 FY | 1.23 Billion INR | -4.89% |
| 2014 Q4 | 320.46 Million INR | -1.64% |
| 2014 Q3 | 325.79 Million INR | 12.02% |
| 2014 Q2 | 290.83 Million INR | -1.1% |
| 2014 Q1 | 294.06 Million INR | -2.0% |
| 2013 Q4 | 300.05 Million INR | -10.22% |
| 2013 FY | 1.29 Billion INR | 4.52% |
| 2013 Q1 | 293.52 Million INR | -14.04% |
| 2013 Q2 | 357.27 Million INR | 21.72% |
| 2013 Q3 | 334.21 Million INR | -6.46% |
| 2012 Q2 | 301.9 Million INR | -0.29% |
| 2012 Q3 | 296.63 Million INR | -1.75% |
| 2012 Q4 | 341.45 Million INR | 15.11% |
| 2012 FY | 1.23 Billion INR | -1.66% |
| 2012 Q1 | 302.76 Million INR | 0.0% |
| 2011 FY | 1.25 Billion INR | -9.24% |
| 2010 FY | 1.38 Billion INR | 262.88% |
| 2009 FY | 382.36 Million INR | 36.14% |
| 2008 FY | 280.86 Million INR | -8.98% |
| 2007 FY | 308.56 Million INR | 97.2% |
| 2006 FY | 156.46 Million INR | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 15.86 Billion INR | 93.076% |
| Aurobindo Pharma Limited | 39.23 Billion INR | 97.199% |
| Glenmark Life Sciences Limited | 11.64 Billion INR | 90.561% |
| Granules India Limited | 7.18 Billion INR | 84.701% |
| Indoco Remedies Limited | 4.74 Billion INR | 76.861% |
| Achyut Healthcare Limited | 1.6 Million INR | -68190.864% |
| Ajanta Pharma Limited | 30.46 Billion INR | 96.393% |
| Alkem Laboratories Limited | 32.83 Billion INR | 96.654% |
| Alpa Laboratories Limited | 156.14 Million INR | -603.696% |
| Brooks Laboratories Limited | 51.18 Million INR | -2046.932% |
| AstraZeneca Pharma India Limited | 2.6 Billion INR | 57.745% |
| Bajaj HealthCare Limited | 985.34 Million INR | -11.514% |
| Bliss GVS Pharma Limited | 1.41 Billion INR | 22.577% |
| Dr. Reddy's Laboratories Limited | 95.87 Billion INR | 98.854% |
| Eris Lifesciences Limited | 4.94 Billion INR | 77.77% |
| FDC Limited | 5.34 Billion INR | 79.456% |
| Glenmark Pharmaceuticals Limited | 67.56 Billion INR | 98.374% |
| Gufic Biosciences Limited | 1.07 Billion INR | -1.957% |
| Ind-Swift Laboratories Limited | 2.12 Billion INR | 48.272% |
| Ipca Laboratories Limited | 13.91 Billion INR | 92.103% |
| Jagsonpal Pharmaceuticals Limited | 773.41 Million INR | -42.072% |
| Krebs Biochemicals & Industries Limited | 46.15 Million INR | -2280.622% |
| Lasa Supergenerics Limited | 291.17 Million INR | -277.369% |
| Laurus Labs Limited | 3.01 Billion INR | 63.505% |
| Lupin Limited | 95.67 Billion INR | 98.852% |
| Mankind Pharma Limited | 23.15 Billion INR | 95.254% |
| Medicamen Biotech Limited | 335.16 Million INR | -227.837% |
| Medico Remedies Limited | 161.84 Million INR | -578.925% |
| Megasoft Limited | 49.52 Million INR | -2118.543% |
| NATCO Pharma Limited | 10.05 Billion INR | 89.075% |
| Piramal Pharma Limited | 19.91 Billion INR | 94.482% |
| RPG Life Sciences Limited | 1.63 Billion INR | 32.816% |
| Sigachi Industries Limited | 579.88 Million INR | -89.485% |
| Sun Pharmaceutical Industries Limited | 154.18 Billion INR | 99.287% |
| Suven Pharmaceuticals Limited | 1.4 Billion INR | 21.67% |
| Syncom Formulations (India) Limited | 942.39 Million INR | -16.596% |
| Unichem Laboratories Limited | 6.72 Billion INR | 83.663% |
| Wanbury Limited | 1.16 Billion INR | 5.351% |
| Windlas Biotech Limited | 1 Billion INR | -9.169% |
| ZIM Laboratories Limited | 1.01 Billion INR | -8.464% |
| Zydus Lifesciences Limited | 43.17 Billion INR | 97.455% |
| Sun Pharma Advanced Research Company Limited | 3.07 Billion INR | 64.288% |
| Divi's Laboratories Limited | 14.17 Billion INR | 92.246% |
| Hester Biosciences Limited | 908.84 Million INR | -20.901% |
| Procter & Gamble Health Limited | 2.99 Billion INR | 63.317% |
| Amrutanjan Health Care Limited | 1.09 Billion INR | 0.017% |
| Bal Pharma Limited | 389.89 Million INR | -181.823% |
| Strides Pharma Science Limited | 9.16 Billion INR | 88.007% |
| Venus Remedies Limited | 1.91 Billion INR | 42.66% |
| Aarti Pharmalabs Limited | 3.07 Billion INR | 64.26% |
| Nectar Lifesciences Limited | 625.55 Million INR | -75.653% |
| Shilpa Medicare Limited | 2.18 Billion INR | 49.61% |
| Aarti Drugs Limited | 1.16 Billion INR | 5.883% |
| Suven Life Sciences Limited | 109.75 Million INR | -901.185% |
| Ind-Swift Limited | 946.56 Million INR | -16.083% |
| Valiant Laboratories Limited | 36.28 Million INR | -2927.915% |
| J. B. Chemicals & Pharmaceuticals Limited | 8.41 Billion INR | 86.946% |
| Solara Active Pharma Sciences Limited | 4.57 Billion INR | 76.007% |
| Themis Medicare Limited | 782.85 Million INR | -40.358% |
| Hikal Limited | 2.48 Billion INR | 55.807% |
| Torrent Pharmaceuticals Limited | 21.42 Billion INR | 94.871% |
| Sequent Scientific Limited | 2.9 Billion INR | 62.134% |
| Novartis India Limited | 470.1 Million INR | -133.738% |
| Wockhardt Limited | 6.4 Billion INR | 82.831% |
| Jubilant Pharmova Limited | 14.45 Billion INR | 92.398% |
| Biofil Chemicals and Pharmaceuticals Limited | 16.2 Million INR | -6678.658% |
| Neuland Laboratories Limited | 2.92 Billion INR | 62.495% |
| Morepen Laboratories Limited | 1.98 Billion INR | 44.713% |
| Kilitch Drugs (India) Limited | 412.42 Million INR | -166.423% |
| Mangalam Drugs & Organics Limited | 676.14 Million INR | -62.509% |